Compass Pathways lays out how clinics could deliver psilocybin if FDA approves it

One week after Compass Pathways submitted its psilocybin application, Steve Levine described how clinics could prepare to deliver it if approved.

Author
HDM Staff
Save
Share
Four participants seated on the Revv Stage during the psychedelics panel.
Photo credit: HLTH USA 2026.

    LAS VEGAS — A week after Compass Pathways submitted its psilocybin application to the Food and Drug Administration, its chief patient officer told a HLTH audience that clinics would need multidisciplinary teams and specialized training to deliver the treatment if it is approved. Steve Levine said the company planned to make training and direct support available to clinics as it prepares for a possible launch.

    Levine spoke on a Revv Stage panel moderated by Law360 senior healthcare reporter Yeji Jesse Lee. Also on the panel were Dr. Lynn Marie Morski, executive director of the Psychedelic Medicine Association, and Sherry Rais, co-founder and CEO of Enthea.

    Preparing clinics and clinicians

    Compass announced on Nov. 9 that it had completed its application for COMP360, an investigational synthetic formulation for treatment-resistant depression. Levine said administration would take place in a “controlled, supervised medical setting” and described the proposed delivery approach as “team based models of care delivery.”

    Levine said a supervised team could draw on psychiatrists, advanced practice nurses, therapists, social workers and other staff. The staffing model would let clinics divide work among clinicians with different credentials while retaining supervision.

    Morski said her association began educating clinicians because “your patients are already asking.” She urged clinicians to learn “the contraindications” and said many still picture recreational use when patients bring up psychedelic medicines.

    Levine expects interventional psychiatry clinics to be among the first sites equipped to offer treatment if the FDA approves it. He pointed to existing clinics that provide in-office treatments requiring hours of observation. Those clinics already have some of the space and staff that a supervised session would require. He said the company would also like to reach other settings, including those outside major urban centers.

    He described a sequence that would start before administration, with preparation and education about what patients might experience. On the treatment day, he said, a team would supervise the session. He described subsequent check-ins focused primarily on safety. That outlines how the company is thinking about delivery while the application is pending. The FDA’s decision and any conditions of approval would determine what a marketed treatment looks like.

    Lee asked how someone would make first contact. Levine said some patients might already see an interventional specialist, while others could come through a referral from a general psychiatrist or therapist. That routing matters because the clinician who manages a patient’s existing medications may work in a different practice from the team that would deliver and monitor the intervention.

    The company says its clinical program includes two phase 3 trials. Its application announcement also cites a phase 2b study, with more than 1,000 participants across the three trials. Those studies are the company’s evidence for the submitted indication. Onstage, Morski said she would like more evidence for people with coexisting conditions that initially kept some patients out of trials.

    Morski also said primary care clinicians would benefit from guidelines that explain who could receive treatment safely. She distinguished the need for clinical education from a clinician’s decision about a particular patient. The first question a patient brings to primary care may be about an advertisement or a news story, long before a specialist considers whether the intervention would be appropriate.

    Who would pay

    Rais said employers are “already spending so much on untreated mental health.” She told Lee that her company, which works with employers, health plans and unions on mental health benefits, was “seeing that already with ketamine therapy,” referring to interest in adding coverage.

    Rais identified “reimbursement and affordability” as conditions for widespread adoption. She said a treatment could be available somewhere in a region and still be out of reach if the patient has to pay for the full visit or travel to a distant site. Employers and insurers would also have to consider the time and space required by supervised visits, beyond the acquisition price of a drug.

    An audience member asked how clinics could provide the human time the panel had described when mental healthcare already faces workforce constraints. Levine said a team could distribute work among credentialed professionals with different roles. He described a way to make more use of available staff, while acknowledging that team-based delivery would address only part of the capacity problem.

    Levine said he was concerned that enthusiasm could move faster than the ability to deliver treatment responsibly. For clinics evaluating readiness, that puts the focus on how a patient is referred, who is present during a session, what happens afterward and how the treatment team shares information with the patient’s usual clinicians. The panel left those as implementation questions for a product still under regulatory review.

    The panel described a possible delivery model and the case its advocates would make to payers. Coverage for COMP360 would depend on regulatory action and subsequent decisions by insurers and employers.

    Levine defined the population in the submission as people with major depression who had been failed by at least two treatments during the current episode. The indication is significant to the delivery question. A clinic would need to establish which treatments the referring clinician had already tried and why those attempts had failed. It would also need a way to return information to the practice that continues to manage the patient’s care.

    Levine separated the supervised administration he described from the question of whether psychotherapy could add benefit. He said that possibility would merit further research, and that the role of psychotherapy should be understood in the context of the actual trials. Morski’s interest in follow-up and additional research reflected a related concern about how patients do after they leave the supervised setting.

    Rais said the prospect of patients seeking substances outside supervised settings was one reason she cared about reaching people who might benefit through formal care. She also said that spending several hours in an altered state could be a barrier for some patients even with a clinic available. The questions she raised about affordability, willingness and safety would persist at different points in a patient’s decision about care.

    For practices preparing now, the panel’s discussion put particular weight on training staff who have never delivered this kind of care and establishing links to the referring clinician. Those are operational choices a medical practice can evaluate before the final requirements for a particular product are known.